Company Overview and News

 
VER / VEREIT, Inc. 424B2 (Prospectus)

2018-10-09 sec.gov
424B2 Table of Contents Filed Pursuant to Rule 424(b)(2) Registration Nos. 333-211204 and 333-211204-01 CALCULATION OF REGISTRATION FEE
VER

 
VER / VEREIT, Inc. 424B2 (Prospectus)

2018-10-09 sec.gov
424B2 Table of Contents Filed Pursuant to Rule 424(b)(2) Registration Nos. 333-211204 and 333-211204-01 CALCULATION OF REGISTRATION FEE
VER

 
VER / VEREIT, Inc. 8-K (Current Report)

2018-10-09 sec.gov
8-K UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, DC 20549
VER

 
VER / VEREIT, Inc. 8-K (Current Report)

2018-10-09 sec.gov
8-K UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, DC 20549
VER

 
VER / VEREIT, Inc. FWP

2018-10-04 sec.gov
FWP ISSUER FREE WRITING PROSPECTUS (RELATING TO PRELIMINARY PROSPECTUS SUPPLEMENT DATED OCTOBER 4, 2018 AND PROSPECTUS DATED MAY 6, 2016) FILED PURSUANT TO RULE 433
VER

 
VER / VEREIT, Inc. FWP

2018-10-04 sec.gov
FWP ISSUER FREE WRITING PROSPECTUS (RELATING TO PRELIMINARY PROSPECTUS SUPPLEMENT DATED OCTOBER 4, 2018 AND PROSPECTUS DATED MAY 6, 2016) FILED PURSUANT TO RULE 433
VER

 
VER / VEREIT, Inc. 424B5 (Prospectus)

2018-10-04 sec.gov
424B5 Table of Contents Filed Pursuant to Rule 424(b)(5) Registration Nos. 333-211204 and 333-211204-01 The information in this preliminary prospectus supplement is not complete and may be changed. This preliminary prospectus supplement is not an offer to sell these securities and we are n
VER

 
VER / VEREIT, Inc. 424B5 (Prospectus)

2018-10-04 sec.gov
424B5 Table of Contents Filed Pursuant to Rule 424(b)(5) Registration Nos. 333-211204 and 333-211204-01 The information in this preliminary prospectus supplement is not complete and may be changed. This preliminary prospectus supplement is not an offer to sell these securities and we are n
VER

 
VER / VEREIT, Inc. 8-K (Current Report)

2018-10-02 sec.gov
8-K UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549
VER

 
VER / VEREIT, Inc. 8-K (Current Report)

2018-10-02 sec.gov
8-K UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549
VER

10
Lexington Realty Trust: Who Sunk My Battleship?

2018-09-26 seekingalpha
Most REITs cut their dividend in 2009, and I can certainly understand a one-time cut in one of the darkest hours in the history of the U.S.
SSREY NYSE O OPRF SHLD VER TGT PLD GPT STAG SSREF

1
The Truth Will Set You Free

2018-09-24 seekingalpha
In Greek mythology, a phoenix is a long-lived bird that is re-born and makes a miraculous comeback.
STOR VER CCPT O OPRF NNN

1
10 Monthly Dividend Stocks to Buy to Pay the Bills

2018-09-23 investorplace
I like making money in the stock market, but I love dividends. You see, the problem with capital gains is that to actually enjoy them, you have to sell your shares. The beauty of dividend stocks is that you get to enjoy the fruits of your investment without having to actually sell anything. Think of it as milking a cow rather than killing it for meat. Which sounds like the better long-term plan to you?
RNP EVV O MAIN LTC OPRF PSEC VER MSCA.CL EPR MSCA PBB STAG

1
Net Lease REITs: Rates, Retail, Risk

2018-09-07 seekingalpha
Love them or hate them. Net lease REITs are the most polarizing real estate sector given their exposure to interest rates and retail, two factors that many investors deliberately avoid.
STOR VER O WPC OPRF

94
Tracking Larry Robbins' Glenview Capital Management Portfolio - Q2 2018 Update

2018-09-03 seekingalpha - 1
Glenview Capital Management's 13F portfolio value decreased from $17.10B to $14.66B this quarter. The number of positions decreased from 52 to 49.
LOW ATHTF FLEX LBTY WBA ENL CVS HPE SHPG NWL LBTYK LILAB WMB DOW MTOR CAH DXC AET CMCSK IQV EBAY MIK TMUSP TMUS BKD CBS.WD VER CNDT GOOGL LILAK RLGY MSFT CPV MHK ENDP FB PAH TMO CCV MCK CCZ GOOG DLPH CHTR AGN DXC.WI CI ARMK HOLX CBS CSC CBS.A CMCSA FTI.WI FMC LBTYB LBTYA FDX ANTM HUM DWDP ABC V CCV.CL FDC THC APTV ANTX LILA

Related Articles

ALIM: Alimera Sciences Analysis and Research Report

2018-10-01 - Asif

Overview The following discussion and analysis should be read in conjunction with its unaudited interim condensed consolidated financial statements and the related notes that appear elsewhere in this quarterly report on Form 10-Q. This discussion contains forward-looking statements reflecting its current expectations that involve risks and uncertainties. Actual results may differ materially from those discussed in these forward-looking statements due to a number of factors, including those set forth in the section entitled “Risk Factors” in its most recent annual report on Form 10-K. For further information regarding forward-looking statements, please refer to the “Special Note Regarding Forward-Looking Statements and Projections” immediately after the index to this quarterly report on Form 10-Q. Alimera Sciences, Inc., and its subsidiaries (we or Alimera), is a pharmaceutical company that specializes in the commercialization and development of prescription ophthalmic pharma...

DMPI: DelMar Pharmaceuticals Analysis and Research Report

2018-09-25 - Asif

Background DelMar Pharmaceuticals, Inc. is a clinical stage drug development company with a focus on the treatment of cancer. The company's mission is to benefit patients and create shareholder value by developing and commercializing anti-cancer therapies for patients whose tumors exhibit features that make them resistant to, or unlikely to respond to, currently available therapies, particularly for orphan cancer indications where patients have failed, or are unlikely to respond to, currently available therapy. DelMar Pharmaceuticals is developing VAL-083, a novel, DNA-targeting agent, for the treatment of glioblastoma multiforme (“GBM”) and potentially other solid tumors, including ovarian cancer. VAL-083 is a first-in-class, DNA-targeting chemotherapeutic that demonstrated activity against a range of tumor types in prior Phase 1 and Phase 2 clinical studies sponsored by the US National Cancer Institute (“NCI”). The company's recent research has highlighted the opportunit...

RIGL: Rigel Pharmaceuticals Analysis and Research Report

2018-09-18 - Asif

Overview Rigel Pharmaceuticals is a biotechnology company dedicated to discovering, developing and providing novel small molecule drugs that significantly improve the lives of patients with immune and hematologic disorders, cancer and rare diseases. The company's pioneering research focuses on signaling pathways that are critical to disease mechanisms. The company's first FDA-approved product is TAVALISSE™ (fostamatinib disodium hexahydrate), an oral spleen tyrosine kinase (SYK) inhibitor, for the treatment of adult patients with chronic immune thrombocytopenia who have had an insufficient response to a previous treatment. The company's current clinical programs include Phase 2 studies of fostamatinib in autoimmune hemolytic anemia and IgA nephropathy, and a Phase 1 study for its IRAK program. In addition, Rigel Pharmaceuticals has product candidates in development with partners BerGenBio AS, Daiichi Sankyo, and Aclaris Therapeutics. Since inception, Rigel Pharmaceuticals h...

Silicon Investor Message Boards

This table lists all message boards related to VER / VEREIT, Inc. on message board site Silicon Investor.

OLED Universal Display Corp OLED Universal Display Corp OLED Universal Display Corp Speculating in Takeover Targets Speculating in Takeover Targets Speculating in Takeover Targets
Severe Weather and the Economic Impact Severe Weather and the Economic Impact Severe Weather and the Economic Impact Severe weather events, climate change and economics Severe weather events, climate change and economics Severe weather events, climate change and economics
Books, Movies, Food, Wine, and Whatever Books, Movies, Food, Wine, and Whatever Books, Movies, Food, Wine, and Whatever Driverless autos, trucks, taxis etc. Driverless autos, trucks, taxis etc. Driverless autos, trucks, taxis etc.
The Beaver Lodge The Beaver Lodge The Beaver Lodge College Football: Nits, Gators, Bruins, Vols - Whoever! College Football: Nits, Gators, Bruins, Vols - Whoever! College Football: Nits, Gators, Bruins, Vols - Whoever!
Verde Agritech Verde Agritech Verde Agritech Off Topic (Every Day Technology) Off Topic (Every Day Technology) Off Topic (Every Day Technology)
CUSIP: 02917T104